Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12395178 | 0.74 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31389937 | 0.74 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22734182 | 0.70 | GRM1 (0.43) | — | |
| SCHEMBL13586024 | 0.69 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1009034 | 0.69 | CCR1 (0.41) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15689524 | 0.69 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20674652 | 0.69 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13400630 | 0.65 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4569220 | 0.65 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31389766 | 0.60 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130611-B2 | Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2018-11-20 | — | — | US | disclosed |
| US-20120283300-A1 | USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS | SNU R&DB FOUNDATION (KR) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130611-B2 | Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis | MKI67, KISS1R, NPY1R | PI4KA 4227/4885PI4K2B 4273/4885PI4K2A 4346/4885 |
| US-20120283300-A1 | USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS | MKI67, KISS1R, NPY1R | PI4KA 4227/4885PI4K2B 4273/4885PI4K2A 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.